Renaissance Technologies LLC Has $5.36 Million Position in OPKO Health, Inc. (NASDAQ:OPK)

Renaissance Technologies LLC reduced its position in shares of OPKO Health, Inc. (NASDAQ:OPK – Get Rating) by 27.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,836,343 shares of the biotechnology company’s stock after selling 1,053,829 shares during the quarter. Renaissance Technologies LLC’s holdings in OPKO Health were worth $5,361,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in OPK. Guggenheim Capital LLC purchased a new position in shares of OPKO Health during the 1st quarter valued at $38,000. Point72 Hong Kong Ltd purchased a new position in shares of OPKO Health during the 1st quarter valued at $39,000. Humankind Investments LLC purchased a new position in shares of OPKO Health during the 3rd quarter valued at $25,000. Beacon Pointe Advisors LLC purchased a new position in shares of OPKO Health during the 1st quarter valued at $49,000. Finally, Verition Fund Management LLC purchased a new position in shares of OPKO Health during the 2nd quarter valued at $36,000. 23.49% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Thursday.

OPKO Health Stock Up 2.5 %

OPKO Health stock opened at $1.24 on Friday. The firm has a market cap of $958.09 million, a price-to-earnings ratio of -2.82 and a beta of 1.64. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.85 and a quick ratio of 1.50. OPKO Health, Inc. has a fifty-two week low of $1.00 and a fifty-two week high of $3.78. The firm has a fifty day moving average price of $1.27 and a two-hundred day moving average price of $1.57.

OPKO Health (NASDAQ:OPK – Get Rating) last released its earnings results on Thursday, February 23rd. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). The firm had revenue of $185.40 million during the quarter, compared to analyst estimates of $168.21 million. OPKO Health had a negative net margin of 32.70% and a negative return on equity of 15.77%. The business’s revenue was down 53.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.11) EPS. As a group, analysts forecast that OPKO Health, Inc. will post -0.32 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost acquired 1,000,000 shares of the business’s stock in a transaction dated Wednesday, March 8th. The stock was acquired at an average price of $1.18 per share, with a total value of $1,180,000.00. Following the completion of the transaction, the chief executive officer now owns 199,831,694 shares of the company’s stock, valued at $235,801,398.92. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Phillip Md Et Al Frost acquired 1,000,000 shares of the business’s stock in a transaction dated Wednesday, March 8th. The stock was acquired at an average price of $1.18 per share, with a total value of $1,180,000.00. Following the completion of the transaction, the chief executive officer now owns 199,831,694 shares of the company’s stock, valued at $235,801,398.92. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Opko Health, Inc. acquired 14,285,714 shares of the business’s stock in a transaction dated Thursday, January 26th. The shares were bought at an average cost of $0.35 per share, with a total value of $4,999,999.90. Following the transaction, the insider now directly owns 94,285,714 shares of the company’s stock, valued at approximately $32,999,999.90. The disclosure for this purchase can be found here. Company insiders own 40.97% of the company’s stock.

OPKO Health Profile

(Get Rating)

OPKO Health, Inc is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations.